MedTrace Logo

Cognitive Enhancement in Bipolar Disorder

NCT00597896 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-06-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine whether the medication pramipexole (Mirapex) may be able to improve cognitive problems (i.e. difficulties with thinking, memory, and concentration) that may be associated with bipolar disorder.

Conditions

Interventions

DRUG

pramipexole

po pramipexole versus matching placebo minimum 0.125 mg bid and maximum 0.75 mg bid

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Northwell Health

    lead OTHER

Principal Investigators

  • Anil K. Malhotra, MD · Northwell Health

  • Katherine Burdick, PhD · Northwell Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00597896 on ClinicalTrials.gov